References

• 2005Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000271 cited
• 2003Bioequivalence and other unresolved issues in generic drug substitution213 cited
• 2005What do primary care patients think about generic drugs?166 cited
• 2006Patients’ attitudes towards and experiences of generic drug substitution in Norway153 cited
• 2010Generic and therapeutic substitutions in the UK: are they a good thing?149 cited
• 1996Lessons from international experience in controlling pharmaceutical expenditure. I: influencing patients128 cited
• 2004What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden106 cited
• 2008Generic substitution in the treatment of epilepsy: Patient and physician perceptions102 cited
• 1995Changing to generic formulary: how one fundholding practice reduced prescribing costs92 cited
• 2009The risks and costs of multiple-generic substitution of topiramate79 cited
• 1996Fortnightly Review: Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors76 cited
• 1996Generic Drugs68 cited
• 1988Medical and Economic Consequences of a Blinded Oral Anticoagulant Brand Change at a Municipal Hospital58 cited
• 1999